An essential nutrient the liver handles selectively, favouring the alpha form. Benefit clusters where starting levels are low: halting nerve damage in people who cannot absorb or transport it, reducing signs of liver injury in fatty liver with inflammation. Higher doses interfere with clotting and raise bleeding into the brain. Dose and form decide the direction. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum α-tocopherol | 30–50 µmol/L | Confirms repletion; detects excess |
| α-Tocopherol : total lipid ratio | Above 2.2 µmol/mmol | Corrects the reading for blood fat level |
| Serum γ-tocopherol | No established target; track change from own baseline, a fall above 50% indicating displacement | Detects isoform displacement by supplemental α-tocopherol |
| International normalised ratio (INR) | 0.9–1.1 if not anticoagulated | Detects antagonism of vitamin K-dependent clotting |
| Platelet count | 150–400 × 10⁹/L | Baseline bleeding risk before a platelet-inhibiting supplement |
| Alanine aminotransferase (ALT) | Below 25 U/L in men, below 20 U/L in women | Tracks the liver response, the best-evidenced benefit |
| Prostate-specific antigen (PSA) | Below 1.0 ng/mL at 40–50 years; below 2.5 ng/mL thereafter | Monitors the prostate signal seen at 400 IU/day |
| Fasting lipid panel | Triglycerides below 100 mg/dL; other targets set individually | Required to interpret tocopherol status, which rides on lipoproteins |
Cadence: Baseline before any dose, then serum α-tocopherol and the clotting panel at 12 weeks and every 6–12 months on a stable dose; liver enzymes at 12 and 24 weeks when the indication is steatohepatitis; prostate-specific antigen annually in men